Theriva Biologics, Inc. (TOVX)

NYSEAMERICAN: TOVX · USD

$0.18

-0.00 (-1.1%)· Recorded snapshot

Market cap	8.4M
Revenue (ttm)	300K
Net income (ttm)	-13.1M
EPS (ttm)	-$0.42
Shares out	45.9M
Volume	2,377,755.31
Beta	1.26

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 300K
Net income (ttm): -13.1M
EPS (ttm): -$0.42
Market cap: 8.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-101.9

P25 -113.8P50 -46.5P75 -0.9

ROIC-51.6

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All TOVX indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000894158
Company name	Theriva Biologics, Inc.
Country	United States
Country code	US
CUSIP number	87164U508
Earnings date	2026-08-11
Earnings time	bmo
Employees	16
Employees change	-6
Employees growth	-27.27%
Enterprise value	$568,466
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2001
Industry	Biotechnology
IPO date	2006-06-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US87164U5083
Last 10-K release date	2026-03-12
Last earnings date	2026-08-11
Last refreshed	2026-11-04
Last stock split date	2024-08-26
Last stock split type	Reverse
Market cap	$8.4M
Market cap category	Nano-Cap
Options	No
Price	$0.18
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	TOVX
U.S. state	Maryland
Website	https://therivabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-228.99%
EV/Sales	1.89x
FCF / EV yield	-2,245.34%
FCF yield	-152.82%
P/B ratio	0.69x
P/S ratio	27.84x
Price / tangible book value	0.69x
Sector forward P/E	24x
Sector P/E	49.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-4,022%
Pretax margin	-3,872.67%
Profit per employee	$-820,500
Revenue per employee	$18,750
ROA	-21.34%
ROA (5Y)	-22.54%
ROCE	-53.05%
ROE	-101.87%
ROE (5Y)	-67.45%
ROIC	-51.56%
SBC / revenue	217%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	10
Net income growth quarters	4
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-22,000
Depreciation and amortization	$103,000
EBIT	$-12.1M
EBITDA	$-12M
EPS	$-0.42
FCF per share	$-0.28
Financing cash flow	$12.2M
Free cash flow	$-12.8M
Free cash flow minus SBC	$-13.4M
Gross profit	$300,000
Investing cash flow	$-22,000
Net borrowing	$-14,000
Net cash flow	$-785,000
Net income	$-13.1M
Operating cash flow minus SBC	$-13.4M
Operating income	$-12.1M
Revenue	$300,000
Stock-based compensation	$651,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-15.49
Book value per share	$0.27
Debt / equity	0.29
Long-term assets	$21.2M
Long-term liabilities	$10.6M
Net cash (debt)	$7.8M
Net cash / market cap	93.19%
Net cash growth	-15.66%
Net debt / equity	-0.64
Piotroski F-Score	2
Property, plant and equipment	$2M
Shareholders' equity	$12.2M
Tangible book value	$12.2M
Tangible book value per share	$0.27
Total assets	$34.9M
Total cash	$11.3M
Total debt	$3.6M
Total liabilities	$22.7M
WACC	7.85%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$13.7M
Current liabilities	$12.1M
Current ratio	1.13
Net working capital	$-9.2M
Quick ratio	1.09
Working capital	$1.6M
Working capital turnover	0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-834.13%
Dividend yield	0%
Shareholder yield	-834.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-100%
10Y return CAGR	-66.73%
10Y total return	-100%
150-day SMA	$0.25
15Y price change	-100%
15Y return CAGR	-49.46%
15Y total return	-100%
1D price change	-1.09%
1M price change	-19.15%
1M total return	-19.15%
1W price change	-3.19%
1W total return	-3.19%
1Y price change	-41.74%
1Y return CAGR	-41.76%
1Y total return	-41.74%
20-day SMA	$0.20
200-day SMA	$0.24
20Y price change	-100%
20Y return CAGR	-43.58%
20Y total return	-100%
3M price change	-13.33%
3M total return	-13.33%
3Y price change	-98.38%
3Y return CAGR	-74.7%
3Y total return	-98.38%
50-day SMA	$0.22
50-day SMA vs 200-day SMA	50under200
52-week high	$0.49
52-week high date	2026-04-20
52-week low	$0.14
52-week low date	2026-11-02
5Y price change	-99.84%
5Y return CAGR	-72.3%
5Y total return	-99.84%
6M price change	-53.29%
6M total return	-53.29%
All-time high	$262,502.33
All-time high date	2007-01-04
All-time low	$0.14
All-time low date	2026-11-02
Average true range (ATR)	$0.02
Average volume	5.2M
Beta (1Y)	1.74
Beta (2Y)	1.41
Beta (5Y)	1.26
Change from 52-week high	-63.01%
Change from 52-week low	33.73%
Change from all-time high	-100%
Change from all-time low	33.73%
Change from open	-1.62%
Day's gap	0.54%
Dollar volume	$432,751
High price	$0.20
Low price	$0.18
Monthly RSI	29.9
Open price	$0.19
Position in 52-week range	18.67%
Previous close	$0.18
Price vs 150-day SMA	-28.6%
Price vs 20-day SMA	-9.77%
Price vs 200-day SMA	-23.91%
Price vs 50-day SMA	-18.09%
Relative volume	0.46
RSI	36.32
Sharpe ratio	-0.01
Sharpe ratio (3Y)	-0.4
Sharpe ratio (5Y)	-0.56
Sortino ratio	0.05
Sortino ratio (3Y)	-0.6
Sortino ratio (5Y)	-0.82
Volume	2.4M
Weekly RSI	38.23
YTD price change	-13.5%
YTD total return	-13.5%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45M
Float percentage	98.12%
Shares change (QoQ)	11.74%
Shares change (YoY)	834.13%
Shares held by insiders	1.88%
Shares held by institutions	4.32%
Shares outstanding	45.9M
Short % of float	4.1%
Short % of shares	4.02%
Short ratio	3.7 days

Deeper analysis on TOVX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TOVX report

Is a complete TOVX research report available?

No complete published report is available for Theriva Biologics, Inc. (TOVX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Theriva Biologics, Inc. (TOVX)

Price

Financial snapshot

Fair-value bridge

Latest news · TOVX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TOVX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TOVX

Frequently asked questions